{"chunk_type":"transcript_chunk","text":"# Anticoagulant Reversal and Hemostasis Emergencies\n## High-level map\n```\nHemostasis emergencies\n├── Anticoagulant reversal\n│   ├── Warfarin: vitamin K (slow) vs PCC (rapid)\n│   └── DOACs: antidote by drug class\n├── Paradoxical thrombosis with low platelets\n│   ├── HIT\n│   └── Kasabach-Merritt syndrome\n└── Treatment-specific complications\n    ├── Pregnancy anticoagulation timing\n    └── EPO-related hypertension/viscosity\n```\n\n## Warfarin reversal principle\n- Life-threatening bleeding needs immediate factor repletion (PCC) plus vitamin K for sustained correction.\n\n## INR without active bleeding framework\n| INR range | Typical action |\n| --- | --- |\n| <4.5 | dose adjust/brief hold |\n| 4.5-10 | hold warfarin (often no routine vitamin K) |\n| >10 | oral vitamin K if no major bleed |\n\n## Operational pearl\n- In critical intracranial or major bleed, do not rely on vitamin K alone for immediate hemostasis.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-306","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology","mnemonic","tree"]}
{"chunk_type":"transcript_chunk","text":"# DOAC Reversal, Pregnancy Anticoagulation, and HIT\n## DOAC reversal matching\n- Factor Xa inhibitors (for example apixaban/rivaroxaban): andexanet alfa pathway.\n- Dabigatran: idarucizumab pathway.\n\n## Pregnancy anticoagulation strategy\n- LMWH is preferred during pregnancy due to fetal safety profile.\n- Near delivery, switch to unfractionated heparin to allow rapid reversal/timing around neuraxial anesthesia and labor.\n\n## HIT core logic\n- Platelet fall after heparin exposure can indicate immune platelet activation with thrombosis risk rather than simple bleeding risk.\n- Use 4Ts for pretest probability; stop all heparin immediately when suspected.\n- Start non-heparin anticoagulant (for example argatroban/fondaparinux pathway).\n- Avoid platelet transfusion in standard HIT because it can worsen thrombosis.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-326","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# EPO Hypertension, Kasabach-Merritt, and Rapid Reversal Recap\n## EPO-associated hypertension\n- Rising hematocrit/viscosity and endothelial signaling effects can provoke severe hypertension.\n- Monitor blood pressure and iron availability during EPO therapy.\n\n## Kasabach-Merritt syndrome\n- Vascular tumor traps/consumes platelets -> consumptive coagulopathy with bleeding risk.\n- Requires urgent multidisciplinary control of tumor and hemostatic instability.\n\n## High-yield scenario table\n| Scenario | Problem | Key action |\n| --- | --- | --- |\n| warfarin + intracranial bleed | urgent factor deficiency state | PCC + IV vitamin K |\n| apixaban bleed | Xa inhibition | andexanet pathway |\n| near-term pregnancy on LMWH | neuraxial/labor timing issue | switch to UFH |\n| HIT with thrombocytopenia | immune prothrombotic state | stop heparin, start non-heparin anticoagulant |\n| EPO with headache/blurred vision | hypertensive hyperviscosity signal | immediate BP reassessment and treatment |","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-346","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Lymphangitis and Blood Product Modification\n## Lymphangitis vs sporotrichosis tempo\n- Acute tender red streaking from skin break over hours suggests bacterial lymphangitis (often streptococcal pattern).\n- Slower nodular spread over weeks suggests sporotrichosis branch.\n\n## Initial antimicrobial principle\n- Typical non-bite uncomplicated rapid lymphangitis pattern is usually treated with strep-focused beta-lactam coverage.\n- Exposure history (animal bite/water/soil context) modifies organism coverage.\n\n## Blood product modifications\n1. Washed RBCs: for IgA deficiency with severe allergic/anaphylactic transfusion history.\n2. Irradiated products: prevent transfusion-associated GVHD in immunocompromised/family-donor contexts.\n3. Leukoreduced products: reduce febrile non-hemolytic reactions and CMV transmission risk in selected populations.\n\n## Core operational rule\n- Choose product modification based on recipient risk profile before transfusion starts.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-366","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Acute Transfusion Reactions + TRALI/TACO + Septic Thrombophlebitis\n## Reaction timing table\n| Reaction | Typical timing | Hallmark clue | Immediate management |\n| --- | --- | --- | --- |\n| Anaphylaxis | minutes | hypotension/wheeze/shock | stop transfusion + IM epinephrine |\n| Acute hemolytic | early (<1 h) | fever, pain, hemoglobinuria | stop transfusion, aggressive support/renal protection |\n| Febrile non-hemolytic | 1-6 h | fever/chills without hemolysis | supportive antipyretic care |\n| Delayed hemolytic | days-weeks | gradual Hb drop/jaundice | monitor and targeted follow-up |\n\n## TRALI vs TACO bedside split\n- TRALI: inflammatory capillary leak, often hypotension/non-cardiogenic pulmonary edema pattern.\n- TACO: hydrostatic volume overload, often hypertension and diuretic responsiveness.\n\n## Septic thrombophlebitis\n- Persistent bacteremia + palpable tender venous cord around line territory suggests infected thrombus.\n- Management sequence: remove line, targeted antibiotics, anticoagulation consideration, surgical source control if purulence/refractory sepsis.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-386","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Infectious Streaks and Transfusion Emergencies\n| Scenario | Likely diagnosis | Next step |\n| --- | --- | --- |\n| rapid red streaks from skin injury | acute lymphangitis | strep-focused antibiotics and source assessment |\n| transfusion-related anaphylaxis | severe allergic reaction | stop transfusion and give epinephrine |\n| blood from first-degree relative | TA-GVHD risk context | request irradiated blood product |\n| dyspnea + hypotension during transfusion | TRALI pattern | supportive respiratory care |\n| dyspnea + hypertension during transfusion | TACO pattern | diuresis and volume management |\n| central line fever + palpable cord | septic thrombophlebitis | line removal + antibiotics ± procedural control |\n\n## Cleanup\n- Removed nonessential caveat text while preserving diagnostic timing and product-selection rules.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-405","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"# Pediatric Hematology Framework (RBC High/Low + Pancytopenia)\n## Structural map\n```\nPediatric hematology\n├── RBC excess\n│   └── neonatal polycythemia\n├── RBC deficiency\n│   ├── production-side anemia (prematurity, iron deficiency)\n│   └── hemolytic/genetic differentials (for example thalassemia)\n└── Pancytopenia\n    ├── marrow production failure (aplastic pathways)\n    └── infiltration/sequestration (leukemia/hypersplenism)\n```\n\n## Purpose\n- Organize infant/toddler anemia and cytopenia evaluation by mechanism rather than isolated lab labels.\n- Emphasize diagnostic branch points used in urgent pediatric triage.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-415","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","tree"]}
{"chunk_type":"transcript_chunk","text":"# Neonatal Polycythemia\n## Clinical pattern\n- Plethoric \"red\" infant with high hematocrit concern.\n- Risk factors include intrauterine hypoxia and delayed cord clamping with increased transfused blood volume.\n\n## Pathophysiology and risk\n- Elevated viscosity can impair microcirculatory flow and increase organ perfusion complications.\n\n## Sampling trap\n- Capillary heel-stick hematocrit may overestimate true value.\n- Confirm with venous sample before definitive diagnosis/treatment.\n\n## Management\n- Venous Hct >65% supports diagnosis.\n- Asymptomatic cases often managed with hydration/monitoring.\n- Symptomatic hyperviscosity may require partial exchange transfusion.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-435","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Anemia of Prematurity and Milk-Associated Iron Deficiency\n## Anemia of prematurity\n- Transitional EPO physiology plus iatrogenic phlebotomy losses drive anemia in preterm infants.\n- Minimize unnecessary blood draws; transfusion decisions depend on symptoms/hemodynamic context.\n\n## Milk-associated iron deficiency (toddler pattern)\n- Excess cow's milk contributes through low iron content, displacement of iron-rich foods, and occult GI blood loss risk.\n- Classic clues: pallor, irritability, pica/pagophagia.\n\n## Management anchors\n- Limit milk intake and provide iron replacement.\n- Reassess diet quality and response with follow-up hemoglobin/indices.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-455","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Mentzer Index and Pancytopenia Workup\n## Mentzer index\n| Condition | Mentzer index | Typical interpretation |\n| --- | --- | --- |\n| Iron deficiency anemia | >13 | lower RBC count with microcytosis from substrate deficiency |\n| Thalassemia trait | <13 | relatively preserved/high RBC count despite microcytosis |\n\n## Pancytopenia branch logic\n- Production failure: aplastic marrow syndromes (hypocellular/fatty marrow pattern).\n- Infiltration/sequestration: leukemia or hypersplenism pathways.\n\n## Physical exam pearl\n- Splenomegaly supports sequestration/infiltration branches more than pure aplastic production failure.\n\n## Next-step strategy\n- Combine CBC/smear findings with marrow-directed evaluation when indicated.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-475","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Pediatric Hematology Numbers\n| Number | Context | Clinical use |\n| --- | --- | --- |\n| 65% | venous Hct threshold | supports neonatal polycythemia diagnosis |\n| 24 oz/day | toddler cow-milk limit | lowers milk-anemia risk |\n| 13 | Mentzer index cutoff | >13 IDA, <13 thalassemia trait tendency |\n\n## High-yield reminders\n- Confirm polycythemia with venous sample, not heel-stick alone.\n- Excess milk intake is a frequent reversible cause of toddler iron-deficiency anemia.\n- Use mechanism-based triage for pancytopenia (production vs infiltration/sequestration).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-492","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap"]}
{"chunk_type":"transcript_chunk","text":"# MSK/Rheum Curriculum Mapping (LM_OSRHM)\n## Program structure overview\n- Part 1: inflammatory vs non-inflammatory arthritic syndromes and systemic autoimmune rheumatology.\n- Part 2: regional pain and sports medicine by anatomic region.\n- Part 3: trauma, bone pathology/tumors, vasculitis/myopathy, pediatric orthopedics.\n\n## Episode map highlights\n| Block | Episode focus | High-yield anchor |\n| --- | --- | --- |\n| Arthritis core | OA, gout/pseudogout, septic arthritis, DGI, TMJ | must not miss septic monoarthritis |\n| Autoimmune I/II | RA, SLE/APLA, seronegative spondyloarthropathy, Sjogren, scleroderma/Raynaud | systemic pattern recognition |\n| Regional pain | shoulder/elbow, hand/wrist, spine, hip/knee, foot/ankle | anatomy-first differential |\n| Trauma/pathology/peds | fractures/complications, bone disease/tumors, vasculitis/myopathy, limping child | emergency triage + age-based diagnosis |","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-1","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# MSK/Rheum Deep Dive Orientation\n## Core objective\n- Build diagnostic speed for acute monoarthritis and broad joint-pain differentials while preserving safety for emergent causes.\n\n## Must-not-miss competencies\n1. Differentiate septic arthritis from crystal/mechanical causes rapidly.\n2. Interpret synovial fluid analysis under exam and clinical constraints.\n3. Apply pediatric limping-child decision logic (including Kocher-style septic hip risk cues).\n4. Recognize DGI and fight-bite related escalation pathways.\n5. Use staged management logic for OA and inflammatory arthritides.\n\n## Study integration note\n- This orientation chunk is a roadmap chunk; non-learning narrative text removed and converted to actionable learning targets.","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-21","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment"]}
